Influenza Peptide Vaccine Compositions for Broad HLA Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compositions and methods of peptide vaccines that are optimized based on predicted population immunogenicity to effectively target influenza proteins and enhance the immune response against influenza.
Innovation Solution
The development of nucleic acid sequences encoding specific amino acid sequences, such as SEQ ID NOs: 1 to 80, which are administered to produce peptides displayed by HLA class I or II molecules, either in modified or unmodified forms, to stimulate an immune response against influenza proteins like nucleoprotein, RNA-directed RNA polymerase catalytic subunit, Matrix protein 1, Polymerase basic protein 2, Polymerase acidic protein, and Protein PA-X.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide vaccines are designed to target conserved influenza proteins, then population immunogenicity is improved, but vaccine complexity increases due to need for multiple peptides across different HLA alleles
Solution Approach 1:
The vaccine is segmented into multiple peptide components, each targeting specific conserved regions of influenza proteins (nucleoprotein, polymerase basic protein 2, polymerase acidic protein, matrix protein 1, RNA-directed RNA polymerase catalytic subunit, and protein PA-X). This segmentation allows the vaccine to cover diverse HLA alleles while maintaining manageable composition through modular peptide design
Solution Approach 2:
The vaccine peptides are designed to be universally recognized across multiple HLA class I and class II alleles simultaneously. Each peptide sequence is selected to bind to multiple different HLA molecules, enabling a single vaccine composition to provide broad population coverage without requiring separate vaccines for different genetic groups
2Adaptability or versatility
If multiple influenza protein targets are included in the vaccine, then immune response coverage is improved, but manufacturing complexity increases
Solution Approach 1:
Six different influenza protein targets (nucleoprotein, polymerase basic protein 2, polymerase acidic protein, matrix protein 1, RNA-directed RNA polymerase catalytic subunit, and protein PA-X) are merged into a single vaccine composition. All peptide sequences are synthesized and formulated together in one product, simplifying manufacturing compared to producing separate vaccines for each protein target
Solution Approach 2:
The vaccine employs parameter optimization in peptide sequence selection, focusing on highly conserved regions with specific amino acid sequences that maintain stability across influenza strains. This parameter-based selection (molecular weight 2-11 kDa, specific conservation thresholds) streamlines the manufacturing process by establishing clear selection criteria for peptide inclusion
Data Source
AI summary
Described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 49. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 81 to 143. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 137515 to 137675. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 137682 to 137830.